Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults
Jessica A. Chichester,Brian J. Green,R. Mark Jones,Yoko Shoji,Kazutoyo Miura,Carole A. Long,Cynthia K. Lee,Christian F. Ockenhouse,Merribeth J. Morin,Stephen J. Streatfield,Vidadi Yusibov +10 more
TLDR
The vaccine candidate displays an acceptable safety and tolerability profile and induced Pfs25-specific IgG in a dose dependent manner but low transmission reducing activity implies need for an improved formulation.About:
This article is published in Vaccine.The article was published on 2018-09-18 and is currently open access. It has received 88 citations till now. The article focuses on the topics: Malaria vaccine & Adjuvant.read more
Citations
More filters
Journal ArticleDOI
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.
Saghi Nooraei,Howra Bahrulolum,Zakieh Sadat Hoseini,Camellia Katalani,Abbas Hajizade,Andrew J. Easton,Gholamreza Ahmadian +6 more
TL;DR: Virus-like particles (VLPs) are highly immunogenic and are able to elicit both the antibody and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines.
Journal ArticleDOI
Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.
Masoud Delfi,Rossella Sartorius,Milad Ashrafizadeh,Esmaeel Sharifi,Yapei Zhang,Piergiuseppe De Berardinis,Ali Zarrabi,Rajender S. Varma,Franklin R. Tay,Bryan Ronain Smith,Bryan Ronain Smith,Pooyan Makvandi +11 more
TL;DR: This review sheds light on the growing interest in self-assembled peptides and proteins and their burgeoning applications in cancer treatment and immunotherapy.
Journal ArticleDOI
Antibodies against Plasmodium falciparum malaria at the molecular level.
TL;DR: Recent advances in single-cell antibody cloning technologies have enabled the molecular characterization of monoclonal antibodies against Plasmodium falciparum parasites, which has significantly enhanced understanding of how these antibodies are generated, as well as their epitope specificity and binding modes.
Journal ArticleDOI
Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.
Roos M. de Jong,Surafel K Tebeje,Lisette Meerstein-Kessel,Fitsum G. Tadesse,Fitsum G. Tadesse,Matthijs M. Jore,Will Stone,Teun Bousema,Teun Bousema +8 more
TL;DR: Evidence for naturally acquired anti‐gametocyte immunity and the current state of transmission blocking vaccines (TBV) are summarized and transmission enhancing immunity, increasing the likelihood or intensity of transmission to mosquitoes, is convincingly demonstrated for P. vivax.
Journal ArticleDOI
Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.
Puna Maya Maharjan,Sunghwa Choe +1 more
TL;DR: The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco-produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak as discussed by the authors.
References
More filters
Journal ArticleDOI
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
Selidji T Agnandji,Selidji T Agnandji,Bertrand Lell,Bertrand Lell,José Francisco Fernandes,José Francisco Fernandes,Béatrice Peggy Abossolo,Béatrice Peggy Abossolo,Barbara Gaelle Nfono Ondo Methogo,Barbara Gaelle Nfono Ondo Methogo,Anita Lumeka Kabwende,Anita Lumeka Kabwende,Ayola A. Adegnika,Ayola A. Adegnika,Benjamin Mordmüller,Benjamin Mordmüller,Saadou Issifou,Saadou Issifou,Peter G. Kremsner,Peter G. Kremsner,Jahit Sacarlal,Pedro Aide,Miguel Lanaspa,John J. Aponte,Sonia Machevo,Sozinho Acácio,Helder Bulo,Betuel Sigaúque,Eusebio Macete,Pedro L. Alonso,Salim Abdulla,Salim Abdulla,Nahya Salim,Nahya Salim,Rose Minja,Rose Minja,Maxmillian Mpina,Maxmillian Mpina,Saumu Ahmed,Saumu Ahmed,Ali Ali,Ali Ali,Ali Mtoro,Ali Mtoro,Ali Hamad,Ali Hamad,Paul Mutani,Paul Mutani,Marcel Tanner,Marcel Tanner,Halidou Tinto,Umberto D'Alessandro,Hermann Sorgho,Innocent Valea,Biebo Bihoun,Issa Guiraud,Berenger Kaboré,Olivier Sombié,Robert T. Guiguemdé,Jean-Bosco Ouédraogo,Mary J. Hamel,Simon Kariuki,Martina Oneko,Chris Odero,Kephas Otieno,Norbert Awino,Meredith McMorrow,Vincent Muturi-Kioi,Kayla F. Laserson,Laurence Slutsker,Walter Otieno,Lucas Otieno,Nekoye Otsyula,Stacey M. O. Gondi,Allan Otieno,Victorine Owira,Esther Oguk,George Odongo,Jon Ben Woods,Bernhards Ogutu,Patricia Njuguna,Roma Chilengi,Pauline Akoo,Christine Kerubo,Charity Maingi,Trudie Lang,Ally Olotu,Philip Bejon,Kevin Marsh,Gabriel Mwambingu,Seth Owusu-Agyei,Kwaku Poku Asante,Kingsley Osei-Kwakye,Owusu Boahen,David Dosoo,Isaac Asante,George Adjei,Evans Kwara,Daniel Chandramohan,Brian Greenwood,John Lusingu,John Lusingu,John Lusingu,Samwel Gesase,Samwel Gesase,Samwel Gesase,Anangisye Malabeja,Anangisye Malabeja,Anangisye Malabeja,Omari Abdul,Omari Abdul,Omari Abdul,Coline Mahende,Coline Mahende,Coline Mahende,Edwin Liheluka,Edwin Liheluka,Edwin Liheluka,Lincoln Malle,Lincoln Malle,Lincoln Malle,M.M. Lemnge,M.M. Lemnge,M.M. Lemnge,Thor G. Theander,Thor G. Theander,Thor G. Theander,Chris Drakeley,Chris Drakeley,Chris Drakeley,Daniel Ansong,Tsiri Agbenyega,Samuel Adjei,Harry Owusu Boateng,Theresa Rettig,John Bawa,Justice Sylverken,David Sambian,Anima Sarfo,Alex Agyekum,Francis Martinson,Irving F. Hoffman,Tisungane Mvalo,Portia Kamthunzi,Rutendo Nkomo,Tapiwa Tembo,Gerald Tegha,Mercy Tsidya,Jane Kilembe,Chimwemwe Chawinga,W. Ripley Ballou,Joe Cohen,Yolanda Guerra,Erik Jongert,Didier Lapierre,Amanda J. Leach,Marc Lievens,Opokua Ofori-Anyinam,Aurélie Olivier,Johan Vekemans,Terrell Carter,David C. Kaslow,Didier Leboulleux,Christian Loucq,Afiya Radford,Barbara Savarese,David Schellenberg,Marla Sillman,Preeti Vansadia +168 more
TL;DR: The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants.
Journal ArticleDOI
Virus-like particles: passport to immune recognition.
TL;DR: This review outlines some of the advantages, disadvantages, and technical considerations for the use of a wide range of VLP systems in vaccine development.
Journal ArticleDOI
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu,Ruth D. Ellis,Donna Shaffer,Erica Fontes,Elissa Malkin,Siddhartha Mahanty,Michael P. Fay,David L. Narum,Kelly M. Rausch,Aaron P. Miles,Joan Aebig,Andrew C. Orcutt,Olga Muratova,Guanhong Song,Lynn Lambert,Daming Zhu,Kazutoyo Miura,Carole A. Long,Allan Saul,Louis H. Miller,Anna P. Durbin +20 more
TL;DR: It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine, but these vaccines are unexpectedly reactogenic for further development.
Journal ArticleDOI
A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.
David C. Kaslow,Isabella A. Quakyi,Chiang Syin,Michael G. Raum,David B. Keister,John E. Coligan,Thomas F. McCutchan,Louis H. Miller +7 more
TL;DR: The gene encoding the surface protein of relative molecular mass Mr 25,000, expressed on zygotes and ookinetes of P. falciparum, is cloned and the deduced amino-acid sequence consists of a signal sequence, a hydrophobic C-terminus, and four tandem epidermal growth factor EGF-like domains.
Journal ArticleDOI
Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito.
A. N. Vermeulen,T. Ponnudurai,P. J. A. Beckers,J. P. Verhave,M. A. Smits,J. H. E. T. Meuwissen +5 more
TL;DR: Using a mixture of two blocking mAb reacting against the Mr 48/45 and 25 K proteins, respectively, an additive blocking effect could be demonstrated and it was demonstrated that a combination of mAb recognizing different epitopes on the same protein molecule acted synergistically in inhibiting oocyst formation.
Related Papers (5)
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
Kawsar R. Talaat,Ruth D. Ellis,Janet Hurd,Autumn Hentrich,Erin E. Gabriel,Noreen A. Hynes,Noreen A. Hynes,Kelly M. Rausch,Daming Zhu,Olga Muratova,Raul Herrera,Charles Anderson,David A. Jones,Joan Aebig,Sarah Brockley,Nicholas J. MacDonald,Xiaowei Wang,Michael P. Fay,Sara A. Healy,Anna P. Durbin,David L. Narum,Yimin Wu,Patrick E. Duffy +22 more
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu,Ruth D. Ellis,Donna Shaffer,Erica Fontes,Elissa Malkin,Siddhartha Mahanty,Michael P. Fay,David L. Narum,Kelly M. Rausch,Aaron P. Miles,Joan Aebig,Andrew C. Orcutt,Olga Muratova,Guanhong Song,Lynn Lambert,Daming Zhu,Kazutoyo Miura,Carole A. Long,Allan Saul,Louis H. Miller,Anna P. Durbin +20 more